Frazier Life Sciences XI, L.P., an insider at Attovia Therapeutics, Inc. (ATTO), disclosed an open-market purchase of 588,235 shares on August 6, 2026, according to a Form 4 filed with the SEC. The shares were bought at $17.00 apiece, for a total outlay of $9,999,995.00 — a purchase sized almost exactly to the $10 million mark.
This was not a stock-option exercise, a grant, or any other form of compensation-related transaction. The filing is coded as an open-market buy, meaning Frazier Life Sciences XI used its own capital to acquire the shares at the prevailing market price, the same way any outside investor would.
What the Filing Shows
Following the transaction, Frazier Life Sciences XI now holds 6,154,213 shares of Attovia Therapeutics directly. The size of the purchase relative to the resulting stake suggests this is an entity with a long-standing position in the company rather than a first-time buyer — the newly acquired 588,235 shares represent a small fraction of the more than 6.15 million shares now held.
Attovia Therapeutics trades under the ticker ATTO. Form 4 filings like this one are required whenever a corporate insider — which can include officers, directors, or entities holding more than 10% of a company’s shares — buys or sells stock, and they must generally be filed within two business days of the transaction.
Why Insider Buying Draws Attention
Open-market purchases by insiders are watched more closely by market participants than routine sales, since insiders selling shares can be explained by many personal reasons — diversification, tax planning, or liquidity needs — while a decision to buy more stock with personal or fund capital is a more direct signal about how an insider views the company’s prospects at the current price. Academic research on insider trading patterns has found that clusters of open-market insider buying can, in aggregate across many companies, correlate with periods of subsequent outperformance, though any individual transaction can reflect a wide range of motivations that are not disclosed in the filing itself.
This report is based solely on the details contained in the Form 4 disclosure and does not constitute investment advice or a recommendation to buy or sell shares of Attovia Therapeutics. Readers interested in the underlying filing can consult the original SEC document for further detail.
→ See all ATTO coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.